Payment overview · 2025
General Payments
$543.05
20 reported records · 13 companies
Healthcare provider profile · identity verified
Danielle M Hansen, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ERIE, PA · NPI 1548436389
Verified facts
What the public records show
CMS Open Payments records show Danielle M Hansen, DO received $543.05 in general payments during 2025 across 20 reported records.
Madrigal Pharmaceuticals accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $117.50 | 21.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $77.59 | 14.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $65.52 | 12.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.84 | 11.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.45 | 9.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.97 | 7.7% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.09 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.21 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.22 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.96 | 3.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.97 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.10 | 2.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.63 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $543.05 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $117.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $77.59 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 793 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 445 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 96 |
| Lisinopril | Lisinopril | 413 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 53 |
| Furosemide | Furosemide | 257 | 56 |
| Gabapentin | Gabapentin | 253 | 47 |
| Donepezil Hcl | Donepezil Hcl | 239 | 41 |
| Omeprazole | Omeprazole | 239 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 35 |
| Potassium Chloride | Potassium Chloride | 213 | 41 |
| Xarelto | Rivaroxaban | 172 | 21 |
| Sertraline Hcl | Sertraline Hcl | 156 | 33 |
| Metformin Hcl | Metformin Hcl | 153 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 26 |
| Losartan Potassium | Losartan Potassium | 144 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 28 |
| Memantine Hcl | Memantine Hcl | 133 | 26 |
| Bumetanide | Bumetanide | 132 | 19 |
| Buspirone Hcl | Buspirone Hcl | 120 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 17 |
| Famotidine | Famotidine | 117 | 23 |
| Eliquis | Apixaban | 108 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 16 |
| Trazodone Hcl | Trazodone Hcl | 100 | 27 |
| Olanzapine | Olanzapine | 97 | 12 |
| Mirtazapine | Mirtazapine | 94 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 14 |
| Atenolol | Atenolol | 86 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 21 |
| Simvastatin | Simvastatin | 84 | 16 |
| Montelukast Sodium | Montelukast Sodium | 78 | 18 |
| Meloxicam | Meloxicam | 77 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 75 | 11 |
| Levetiracetam | Levetiracetam | 73 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 65 | 15 |
| Latanoprost | Latanoprost | 65 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Spironolactone | Spironolactone | 62 | 17 |
| Tramadol Hcl | Tramadol Hcl | 62 | 13 |
| Baclofen | Baclofen | 57 | 12 |
| Ezetimibe | Ezetimibe | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 23 |
| Clozapine | Clozapine | 54 | suppressed |
| Allopurinol | Allopurinol | 53 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 15 |
| Metformin Hcl Er | Metformin Hcl | 48 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Carvedilol | Carvedilol | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Tradjenta | Linagliptin | 42 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Lorazepam | Lorazepam | 37 | 14 |
| Nystatin | Nystatin | 37 | 22 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Fentanyl | Fentanyl | 34 | suppressed |
| Metolazone | Metolazone | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Carbamazepine Er | Carbamazepine | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Nyamyc | Nystatin | 30 | 17 |
| Nystop | Nystatin | 30 | 18 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 20 |
| Glipizide | Glipizide | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Admelog | Insulin Lispro | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Levofloxacin | Levofloxacin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Linzess | Linaclotide | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $543.05 · 20 records | Madrigal Pharmaceuticals | ABILIFY ASIMTUFII, AMYVID, AUSTEDO XR, CAPLYTA, EVENITY, FARXIGA, KISUNLA, Korlym, LEQVIO, MOUNJARO, Ozempic, PROCLAIM, PROLIA, QUTENZA, REZDIFFRA, UZEDY, VYEPTI, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error